|
Jun 25
|
Exploring US High Growth Tech Stocks For Potential Opportunities
|
|
Jun 24
|
Blueprint Medicines Presents Strong Long-Term Data for AYVAKIT in Systemic Mastocytosis
|
|
Jun 23
|
Exploring 3 High Growth Tech Stocks In The US Market
|
|
Jun 20
|
Exploring 3 High Growth Tech Stocks in the US Market
|
|
Jun 19
|
Exploring Three High Growth Tech Stocks In The US Market
|
|
Jun 17
|
Exploring High Growth Tech Opportunities in US Markets
|
|
Jun 12
|
Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses
|
|
Jun 3
|
Why Blueprint Medicines Corporation (BPMC) Skyrocketed On Monday
|
|
Jun 2
|
These Stocks Are Moving the Most Today: Cleveland-Cliffs, Tesla, GM, Blueprint Medicines, BioNTech, DraftKings, and More
|
|
Jun 2
|
Sanofi Just Spent $9.5 Billion on a Rare Disease You've Never Heard Of
|
|
Jun 2
|
Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines
|
|
Jun 2
|
M&A is 'lifeblood' of biopharma: Analyst on Sanofi-Blueprint deal
|
|
Jun 2
|
Sanofi to acquire Blueprint Medicines, Boeing upgrade
|
|
Jun 2
|
Sanofi to expand immunology offerings with Blueprint Medicines
|
|
Jun 2
|
Blueprint Medicines Soars 26% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal.
|
|
Jun 2
|
Sanofi to Acquire Blueprint Medicines for up to $9.5 Billion to Expand Immunology Portfolio
|
|
Jun 2
|
Blueprint Medicines Stock Soars as Biotech Agrees to Over $9B Sanofi Takeover
|
|
Jun 2
|
Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout
|
|
Jun 2
|
Sanofi to acquire Blueprint for up to $9.5B
|
|
Jun 2
|
5 Things to Know Before the Stock Market Opens
|